Join us on July 30 to discuss why getting grounded in the CER Collaborative tools is important to your ongoing Hep C and overall specialty drug strategies. Speakers include:
- Sean Karbowicz of OmedaRx will use discuss ICER and how the California Technology Assessment Panel used this methodology to arrive at its HCV recommendations.
- Lynn Nishida, Assistant VP with Solid Benefit Guidance, will discuss how her clients are moving into second-generation decision-making with the training provided by the CER Certificate program.
Event Details Available Here.